SEC FILE NUMBER
001-34921
CUSIP NUMBER
00767E 102
|
|
|
UNITED STATES FORM 12b-25
NOTIFICATION OF LATE FILING |
|
|
|
(Check one) |
|
x Form 10-K |
o Form 20-F |
o Form 11-K |
o Form 10-Q |
o Form 10-D | |
|
|
|
o Form N-SAR |
o Form N-CSR |
|
|
| |
|
|
|
|
|
|
|
| |
|
|
|
For Period Ended: |
December 31, 2015 | ||||
|
|
|
o Transition Report on Form 10-K |
|
| |||
|
|
|
o Transition Report on Form 20-F |
|
| |||
|
|
|
o Transition Report on Form 11-K |
|
| |||
|
|
|
o Transition Report on Form 10-Q |
|
| |||
|
|
|
o Transition Report on Form N-SAR |
|
| |||
|
|
|
For the Transition Period Ended: |
| ||||
|
Read Instruction (on back page) Before Preparing Form. Please Print or Type. |
If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:
Not applicable
PART I — REGISTRANT INFORMATION
|
Aegerion Pharmaceuticals, Inc. |
|
Full Name of Registrant |
|
|
|
|
|
Former Name if Applicable |
|
|
|
One Main Street, Suite 800 |
|
Address of Principal Executive Office (Street and Number) |
|
|
|
Cambridge, Massachusetts 02142 |
|
City, State and Zip Code |
PART II — RULES 12b-25(b) AND (c)
If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)
|
|
(a) |
The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense |
|
x |
(b) |
The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and |
|
|
(c) |
The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable. |
PART III — NARRATIVE
State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-SAR, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.
Aegerion Pharmaceuticals, Inc. (the “Company”) is unable to file its Annual Report on Form 10-K for the year ended December 31, 2015 (the “Form 10-K”) within the prescribed time period without unreasonable effort or expense. Additional time is needed because the Company is finalizing (i) accounting and disclosures related to the ongoing Department of Justice and Securities and Exchange Commission investigations, (ii) analysis and assessment of going concern matters, (iii) acquisition accounting related to its acquisition of MYALEPT assets in January 2015 and (iv) procedures underlying management’s report on control over financial reporting. The Company intends to file the Form 10-K no later than March 15, 2016.
SEC 1344 (04-09) Persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
(Attach extra Sheets if Needed)
PART IV — OTHER INFORMATION
|
(1) |
Name and telephone number of person to contact in regard to this notification | ||||
|
|
Gregory D. Perry |
|
(617) |
|
500-7867 |
|
|
(Name) |
|
(Area Code) |
|
(Telephone Number) |
|
|
| ||||
|
(2) |
Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s). | ||||
|
|
| ||||
|
|
|
|
|
|
x Yes o No |
|
|
|
|
|
|
|
|
(3) |
Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof? | ||||
|
|
| ||||
|
|
|
|
|
|
x Yes o No |
|
|
|
|
|
|
|
|
|
If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.
The Company anticipates that its results of operations for the year ended December 31, 2015 to be included in the Form 10-K will be significantly different than its results of operations for the year ended December 31, 2014. On February 25, 2016, the Company filed a Current Report on Form 8-K with the Securities and Exchange Commission furnishing a press release discussing the 2015 financial results that it expects to include in the Form 10-K and explaining narratively and quantitatively such results and differences between such results and results for the Company’s year ended December 31, 2014. | ||||
Aegerion Pharmaceuticals, Inc.
(Name of Registrant as Specified in Charter)
has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.
|
Date |
February 29, 2016 |
|
By |
/s/ Gregory D. Perry |
|
|
|
|
|
Gregory D. Perry |
|
|
|
|
|
Chief Financial Officer |
INSTRUCTION: The form may be signed by an executive officer of the registrant or by any other duly authorized representative. The name and title of the person signing the form shall be typed or printed beneath the signature. If the statement is signed on behalf of the registrant by an authorized representative (other than an executive officer), evidence of the representative’s authority to sign on behalf of the registrant shall be filed with the form.
|
|
ATTENTION |
|
|
Intentional misstatements or omissions of fact constitute Federal Criminal Violations (See 18 U.S.C. 1001). | ||